Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90

Mariko Yoshida, Taro Yamashita, Hikari Okada, Naoki Oishi, Kouki Nio, Takehiro Hayashi, Yoshimoto Nomura, Tomoyuki Hayashi, Yoshiro Asahina, Mika Ohwada, Hajime Sunagozaka, Hajime Takatori, Federico Colombo, Laura Porretti, Masao Honda, Shuichi Kaneko

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cancer stem cells (CSCs) are a pivotal target for eradicating hepatocellular carcinoma (HCC). We previously reported that distinctive CSCs regulating tumorigenicity (EpCAM+ CSCs) and metastasis (CD90+ CSCs) have different epithelial/mesenchymal gene expression signatures. Here, we examined the influence of sorafenib, a multiple-receptor tyrosine kinase inhibitor used as a first-line treatment for advanced HCC, on EpCAM+ and CD90+ CSCs. CD90+ cells showed higher c-Kit gene/protein expression than EpCAM+ cells. Sorafenib treatment reduced the number of CD90+ cells with attenuated c-Kit phosphorylation, whereas it enriched the EpCAM+ cell population. We evaluated the role of CD90+ and EpCAM+ CSCs in vivo by subcutaneously injecting these CSCs together in immune-deficient mice. We observed that sorafenib subtly affected the suppression of primary tumor growth maintained by EpCAM+ CSCs, but completely inhibited the lung metastasis mediated by CD90+ CSCs. We further evaluated the effect of sorafenib on extracellular vesicle (EV) production and found that sorafenib suppressed the production of EVs containing TGF-β mRNA in CD90+ cells and inhibited the cell-cell communication and motility of EpCAM+ cells. Our data suggest the following novel effects of sorafenib: suppressing CD90+ CSCs and inhibiting the production of EVs regulating distant metastasis.

Original languageEnglish
Article number11292
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Neoplastic Stem Cells
Mesenchymal Stromal Cells
Hepatocellular Carcinoma
Neoplasm Metastasis
sorafenib
Proto-Oncogene Proteins c-kit
Receptor Protein-Tyrosine Kinases
Epithelial Cell Adhesion Molecule
Transcriptome
Cell Communication
Cell Movement
Cell Count
Phosphorylation
Gene Expression
Lung
Messenger RNA

ASJC Scopus subject areas

  • General

Cite this

Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90. / Yoshida, Mariko; Yamashita, Taro; Okada, Hikari; Oishi, Naoki; Nio, Kouki; Hayashi, Takehiro; Nomura, Yoshimoto; Hayashi, Tomoyuki; Asahina, Yoshiro; Ohwada, Mika; Sunagozaka, Hajime; Takatori, Hajime; Colombo, Federico; Porretti, Laura; Honda, Masao; Kaneko, Shuichi.

In: Scientific Reports, Vol. 7, No. 1, 11292, 01.12.2017.

Research output: Contribution to journalArticle

Yoshida, M, Yamashita, T, Okada, H, Oishi, N, Nio, K, Hayashi, T, Nomura, Y, Hayashi, T, Asahina, Y, Ohwada, M, Sunagozaka, H, Takatori, H, Colombo, F, Porretti, L, Honda, M & Kaneko, S 2017, 'Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90', Scientific Reports, vol. 7, no. 1, 11292. https://doi.org/10.1038/s41598-017-11848-z
Yoshida, Mariko ; Yamashita, Taro ; Okada, Hikari ; Oishi, Naoki ; Nio, Kouki ; Hayashi, Takehiro ; Nomura, Yoshimoto ; Hayashi, Tomoyuki ; Asahina, Yoshiro ; Ohwada, Mika ; Sunagozaka, Hajime ; Takatori, Hajime ; Colombo, Federico ; Porretti, Laura ; Honda, Masao ; Kaneko, Shuichi. / Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{1d04284bd2d141459d331edf95a188e8,
title = "Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90",
abstract = "Cancer stem cells (CSCs) are a pivotal target for eradicating hepatocellular carcinoma (HCC). We previously reported that distinctive CSCs regulating tumorigenicity (EpCAM+ CSCs) and metastasis (CD90+ CSCs) have different epithelial/mesenchymal gene expression signatures. Here, we examined the influence of sorafenib, a multiple-receptor tyrosine kinase inhibitor used as a first-line treatment for advanced HCC, on EpCAM+ and CD90+ CSCs. CD90+ cells showed higher c-Kit gene/protein expression than EpCAM+ cells. Sorafenib treatment reduced the number of CD90+ cells with attenuated c-Kit phosphorylation, whereas it enriched the EpCAM+ cell population. We evaluated the role of CD90+ and EpCAM+ CSCs in vivo by subcutaneously injecting these CSCs together in immune-deficient mice. We observed that sorafenib subtly affected the suppression of primary tumor growth maintained by EpCAM+ CSCs, but completely inhibited the lung metastasis mediated by CD90+ CSCs. We further evaluated the effect of sorafenib on extracellular vesicle (EV) production and found that sorafenib suppressed the production of EVs containing TGF-β mRNA in CD90+ cells and inhibited the cell-cell communication and motility of EpCAM+ cells. Our data suggest the following novel effects of sorafenib: suppressing CD90+ CSCs and inhibiting the production of EVs regulating distant metastasis.",
author = "Mariko Yoshida and Taro Yamashita and Hikari Okada and Naoki Oishi and Kouki Nio and Takehiro Hayashi and Yoshimoto Nomura and Tomoyuki Hayashi and Yoshiro Asahina and Mika Ohwada and Hajime Sunagozaka and Hajime Takatori and Federico Colombo and Laura Porretti and Masao Honda and Shuichi Kaneko",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-11848-z",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90

AU - Yoshida, Mariko

AU - Yamashita, Taro

AU - Okada, Hikari

AU - Oishi, Naoki

AU - Nio, Kouki

AU - Hayashi, Takehiro

AU - Nomura, Yoshimoto

AU - Hayashi, Tomoyuki

AU - Asahina, Yoshiro

AU - Ohwada, Mika

AU - Sunagozaka, Hajime

AU - Takatori, Hajime

AU - Colombo, Federico

AU - Porretti, Laura

AU - Honda, Masao

AU - Kaneko, Shuichi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Cancer stem cells (CSCs) are a pivotal target for eradicating hepatocellular carcinoma (HCC). We previously reported that distinctive CSCs regulating tumorigenicity (EpCAM+ CSCs) and metastasis (CD90+ CSCs) have different epithelial/mesenchymal gene expression signatures. Here, we examined the influence of sorafenib, a multiple-receptor tyrosine kinase inhibitor used as a first-line treatment for advanced HCC, on EpCAM+ and CD90+ CSCs. CD90+ cells showed higher c-Kit gene/protein expression than EpCAM+ cells. Sorafenib treatment reduced the number of CD90+ cells with attenuated c-Kit phosphorylation, whereas it enriched the EpCAM+ cell population. We evaluated the role of CD90+ and EpCAM+ CSCs in vivo by subcutaneously injecting these CSCs together in immune-deficient mice. We observed that sorafenib subtly affected the suppression of primary tumor growth maintained by EpCAM+ CSCs, but completely inhibited the lung metastasis mediated by CD90+ CSCs. We further evaluated the effect of sorafenib on extracellular vesicle (EV) production and found that sorafenib suppressed the production of EVs containing TGF-β mRNA in CD90+ cells and inhibited the cell-cell communication and motility of EpCAM+ cells. Our data suggest the following novel effects of sorafenib: suppressing CD90+ CSCs and inhibiting the production of EVs regulating distant metastasis.

AB - Cancer stem cells (CSCs) are a pivotal target for eradicating hepatocellular carcinoma (HCC). We previously reported that distinctive CSCs regulating tumorigenicity (EpCAM+ CSCs) and metastasis (CD90+ CSCs) have different epithelial/mesenchymal gene expression signatures. Here, we examined the influence of sorafenib, a multiple-receptor tyrosine kinase inhibitor used as a first-line treatment for advanced HCC, on EpCAM+ and CD90+ CSCs. CD90+ cells showed higher c-Kit gene/protein expression than EpCAM+ cells. Sorafenib treatment reduced the number of CD90+ cells with attenuated c-Kit phosphorylation, whereas it enriched the EpCAM+ cell population. We evaluated the role of CD90+ and EpCAM+ CSCs in vivo by subcutaneously injecting these CSCs together in immune-deficient mice. We observed that sorafenib subtly affected the suppression of primary tumor growth maintained by EpCAM+ CSCs, but completely inhibited the lung metastasis mediated by CD90+ CSCs. We further evaluated the effect of sorafenib on extracellular vesicle (EV) production and found that sorafenib suppressed the production of EVs containing TGF-β mRNA in CD90+ cells and inhibited the cell-cell communication and motility of EpCAM+ cells. Our data suggest the following novel effects of sorafenib: suppressing CD90+ CSCs and inhibiting the production of EVs regulating distant metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85029312002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029312002&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-11848-z

DO - 10.1038/s41598-017-11848-z

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 11292

ER -